IDiyas

For the Inventor, By the Inventor

Tsukuba, Japan

Norikazu Ohtake

USPTO Granted Patents = 11


Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 16(Granted Patents)


Location History:

  • Okazaki, JP (1994 - 1995)
  • Tsukuba, JP (2009 - 2013)

Company Filing History:

goldMedal7 out of 237 
 
Banyu Pharmaceutical Co. Ltd
 patents
silverMedal4 out of 47 
 
Msd K.k.
 patents

Years Active: 1994-2013

where 'Filed Patents' based on already Granted Patents

11 patents (USPTO):
1. 8609699 - Oxotetrahydrofuran-2-yl-benzimidazole derivative (2013-12-17),
2. 8592428 - Acetyl pyrrolidinyl indole derivative (2013-11-26),
3. 8158652 - Substituted pyridone derivative (2012-04-17),
4. 8044070 - Heteroaryloxy nitrogenous saturated heterocyclic derivative (2011-10-25),
5. 7960402 - Carbamoyl-substituted spiro derivative (2011-06-14),
6. 7834182 - Piperidine derivative (2010-11-16),
7. 7595316 - Heteroaryloxy nitrogenous saturated heterocyclic derivative (2009-09-29),
8. 7547693 - Piperidine derivative (2009-06-16),
9. 5438054 - 2-(substituted pyrrolidinylthio) carbapenem derivatives (1995-08-01),
10. 5374720 - 2-(substituted pyrrolidinylthio)carbapenem derivatives (1994-12-20),
11. 5373002 - 2-(substituted pyrrolidinylthio) carbapenem derivatives (1994-12-13),

Title: Norikazu Ohtake: Innovator in Diabetes Treatment

Introduction

Norikazu Ohtake is an accomplished inventor based in Tsukuba, Japan, recognized for his significant contributions to the field of pharmaceuticals. With a total of 11 patents to his name, Ohtake's innovations focus primarily on compounds aimed at the treatment and prevention of diabetes mellitus and its complications. His inventive work continues to showcase his dedication to improving health outcomes through scientific innovation.

Latest Patents

Ohtake's recent patents include two notable compounds. The first is an "Oxotetrahydrofuran-2-yl-benzimidazole derivative," which is designed to activate glucokinase, aiding in the treatment and prevention of diabetes mellitus, diabetes complications, or obesity. The compounds are specified by a detailed formula where R1 represents a carbamoyl group, R2 is a lower alkyl group, and various other specifications link to groups such as pyridinyl and thiazolyl.

The second patent is for an "Acetyl pyrrolidinyl indole derivative," which features compounds with similar applications in treating diabetes and its complications. This invention emphasizes the glucokinase-activating effects, with R representing a lower alkylsulfonyl group and its variations, which contribute to its therapeutic efficacy.

Career Highlights

Throughout his career, Norikazu Ohtake has made strides in the pharmaceutical industry, having worked with renowned companies such as Banyu Pharmaceutical Co., Ltd., and MSD K.K. His experience in these organizations provided him the foundation to develop impactful innovations in healthcare.

Collaborations

Ohtake has collaborated with notable colleagues, including Shigeru Tokita and Takuya Suga. These partnerships have not only fostered teamwork but also enhanced the creative process behind the developments of their groundbreaking inventions in pharmaceuticals.

Conclusion

Norikazu Ohtake stands out as a pivotal figure in the world of pharmaceutical innovation, particularly concerning diabetes treatment. His extensive portfolio of patents reflects a strong commitment to addressing critical health issues through scientific advancements. With continued collaboration and dedication, Ohtake is expected to further pave the way for significant advancements in the pharmaceutical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…